Russia to end trials of Covid 19 vaccine in late September
Moscow, Sep 8 (Prensa Latina) The second phase of clinical trials with volunteers of the Russian Covid-19 vaccine proposed by Russia's 'Vektor' State Research Center for Virology and Biotechnologies will conclude on September 30, official sources said.
Anna Popova, Head of the Federal Service for the Oversight of Consumer Protection and Welfare and in charge of epidemiological surveillance, pointed out that this vaccine is based on peptide antigens, the injection of which was administrated to the first patients with a 72-hour interval.
Popova explained that the way the tests were performed was suggested by the Russian Ministry of Health as one of the conditions for their subsequent registration, Moscow television said. In addition, the head of the Russian public health watchdog Rospotrebnadzor, to which the 'Vektor' center is attached, pointed out that 0.6% of the Russian population (more than 1.3 million people) contracted SARS-CoV-2 at different levels of complication of that disease.
Some 172 kinds of tests are used in this center to detect the aforementioned disease. More than 38 million tests have been performed since March, making Russia is the leader in that registry for every 100,000 inhabitants, she said.
Russia is also developing the first Covid-19 vaccine registered globally, called Sputnik V, done by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology and the 48 Research Institute at the Ministry of Defense. The vaccine is currently in its third phase of clinical trials.
|By the minute||Most read|